Sold out
Sold out
Sold out
LOAD MORE
You're viewed all 16 products
Brimonidine
References
FAQ's
References
- Thomas, Michael Barrie; Williams, Michael Trevelyan, Process For The Production Of Imidazolines, Pfizer Inc., Panama, GB1463520A, February 2, 1977
- Acheampong, Andrew; Tang-Liu, Diane D. S, Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay, Journal of Pharmaceutical and Biomedical Analysis, Volume: 13, Issue: 8, Pages: 995-1002, 1995
Frequently Asked Questions
What are the risks of Brimonidine impurities?
The risks of Brimonidine impurities can include decreased efficacy, increased toxicity, and harm to patients' safety and health.
Do Brimonidine impurities affect the bioavailability of the drug?
Impurities in Brimonidine affect the drug bioavailability by interfering with drug absorption or metabolism, leading to decreased efficacy or toxicity.
How are impurities in Brimonidine detected?
Impurities in Brimonidine are detected through various analytical techniques, such as HPLC and LC-MS.
What are the temperature conditions required to store Brimonidine impurities?
Brimonidine impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.